Final Analysis of Post‐Marketing Surveillance for Avelumab + Axitinib in Patients With Renal Cell Carcinoma in Japan
ABSTRACT Introduction Avelumab, an anti‐programmed death ligand 1 antibody, was approved in combination with axitinib for curatively unresectable or metastatic renal cell carcinoma (RCC) in Japan in December 2019. Because the pivotal JAVELIN Renal 101 study included a limited number of Japanese pati...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-01-01
|
| Series: | Cancer Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cam4.70275 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832589758304354304 |
|---|---|
| author | Norio Nonomura Taito Ito Masashi Sato Makiko Morita Mie Ogi Masahiro Kajita Mototsugu Oya |
| author_facet | Norio Nonomura Taito Ito Masashi Sato Makiko Morita Mie Ogi Masahiro Kajita Mototsugu Oya |
| author_sort | Norio Nonomura |
| collection | DOAJ |
| description | ABSTRACT Introduction Avelumab, an anti‐programmed death ligand 1 antibody, was approved in combination with axitinib for curatively unresectable or metastatic renal cell carcinoma (RCC) in Japan in December 2019. Because the pivotal JAVELIN Renal 101 study included a limited number of Japanese patients, post‐marketing surveillance (PMS) was required to evaluate outcomes (safety and effectiveness) in patients with RCC who received avelumab + axitinib treatment in clinical practice in Japan. Materials and Methods We report data from prospective, noncomparative, multicenter, observational PMS in patients with RCC who received ≥ 1 dose of avelumab. Patients were enrolled between December 2019 (date of regulatory approval) and May 2021. The primary objective was to evaluate safety, defined as adverse drug reactions (ADRs) of safety specifications occurring during an observation period of ≤ 52 weeks for each patient. The secondary objective was to evaluate effectiveness, including best overall response and overall survival (OS). Results In total, 328 patients were included in the safety and effectiveness analysis sets. Overall, 173 patients (52.7%) had ADRs of safety specifications of any grade, most commonly thyroid dysfunction (n = 69 [21.0%]), infusion reaction (n = 65 [19.8%]), and hepatic disorders (n = 45 [13.7%]). Objective responses occurred in 118 patients (36.0%), including complete or partial responses in 13 (4.0%) and 105 (32.0%), respectively; the disease control rate was 75.6%. The 12‐month OS rate was 83.7% (95% CI, 78.9%–87.4%). Discussion This PMS confirmed the safety, tolerability, and effectiveness of avelumab + axitinib in patients with RCC in clinical practice in Japan, with a benefit–risk profile comparable to that observed in clinical trials. |
| format | Article |
| id | doaj-art-3f4659bc12e64ede9e3d890de5b8f10c |
| institution | Kabale University |
| issn | 2045-7634 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Medicine |
| spelling | doaj-art-3f4659bc12e64ede9e3d890de5b8f10c2025-01-24T08:46:07ZengWileyCancer Medicine2045-76342025-01-01142n/an/a10.1002/cam4.70275Final Analysis of Post‐Marketing Surveillance for Avelumab + Axitinib in Patients With Renal Cell Carcinoma in JapanNorio Nonomura0Taito Ito1Masashi Sato2Makiko Morita3Mie Ogi4Masahiro Kajita5Mototsugu Oya6Department of Urology Osaka University Graduate School of Medicine Osaka JapanMedical Department Merck Biopharma Co., Ltd., Tokyo, Japan, an Affiliate of Merck KGaA Darmstadt GermanyResearch and Development Merck Biopharma Co., Ltd., Tokyo, Japan, an Affiliate of Merck KGaA Darmstadt GermanyGlobal Patient Safety Japan Merck Biopharma Co., Ltd., Tokyo, Japan, an Affiliate of Merck KGaA Darmstadt GermanyGlobal Development Operations Merck Biopharma Co., Ltd., Tokyo, Japan, an Affiliate of Merck KGaA Darmstadt GermanyMedical Department Merck Biopharma Co., Ltd., Tokyo, Japan, an Affiliate of Merck KGaA Darmstadt GermanyDepartment of Urology Keio University School of Medicine Tokyo JapanABSTRACT Introduction Avelumab, an anti‐programmed death ligand 1 antibody, was approved in combination with axitinib for curatively unresectable or metastatic renal cell carcinoma (RCC) in Japan in December 2019. Because the pivotal JAVELIN Renal 101 study included a limited number of Japanese patients, post‐marketing surveillance (PMS) was required to evaluate outcomes (safety and effectiveness) in patients with RCC who received avelumab + axitinib treatment in clinical practice in Japan. Materials and Methods We report data from prospective, noncomparative, multicenter, observational PMS in patients with RCC who received ≥ 1 dose of avelumab. Patients were enrolled between December 2019 (date of regulatory approval) and May 2021. The primary objective was to evaluate safety, defined as adverse drug reactions (ADRs) of safety specifications occurring during an observation period of ≤ 52 weeks for each patient. The secondary objective was to evaluate effectiveness, including best overall response and overall survival (OS). Results In total, 328 patients were included in the safety and effectiveness analysis sets. Overall, 173 patients (52.7%) had ADRs of safety specifications of any grade, most commonly thyroid dysfunction (n = 69 [21.0%]), infusion reaction (n = 65 [19.8%]), and hepatic disorders (n = 45 [13.7%]). Objective responses occurred in 118 patients (36.0%), including complete or partial responses in 13 (4.0%) and 105 (32.0%), respectively; the disease control rate was 75.6%. The 12‐month OS rate was 83.7% (95% CI, 78.9%–87.4%). Discussion This PMS confirmed the safety, tolerability, and effectiveness of avelumab + axitinib in patients with RCC in clinical practice in Japan, with a benefit–risk profile comparable to that observed in clinical trials.https://doi.org/10.1002/cam4.70275avelumabeffectivenesspost‐marketing surveillancerenal cell carcinomasafety |
| spellingShingle | Norio Nonomura Taito Ito Masashi Sato Makiko Morita Mie Ogi Masahiro Kajita Mototsugu Oya Final Analysis of Post‐Marketing Surveillance for Avelumab + Axitinib in Patients With Renal Cell Carcinoma in Japan Cancer Medicine avelumab effectiveness post‐marketing surveillance renal cell carcinoma safety |
| title | Final Analysis of Post‐Marketing Surveillance for Avelumab + Axitinib in Patients With Renal Cell Carcinoma in Japan |
| title_full | Final Analysis of Post‐Marketing Surveillance for Avelumab + Axitinib in Patients With Renal Cell Carcinoma in Japan |
| title_fullStr | Final Analysis of Post‐Marketing Surveillance for Avelumab + Axitinib in Patients With Renal Cell Carcinoma in Japan |
| title_full_unstemmed | Final Analysis of Post‐Marketing Surveillance for Avelumab + Axitinib in Patients With Renal Cell Carcinoma in Japan |
| title_short | Final Analysis of Post‐Marketing Surveillance for Avelumab + Axitinib in Patients With Renal Cell Carcinoma in Japan |
| title_sort | final analysis of post marketing surveillance for avelumab axitinib in patients with renal cell carcinoma in japan |
| topic | avelumab effectiveness post‐marketing surveillance renal cell carcinoma safety |
| url | https://doi.org/10.1002/cam4.70275 |
| work_keys_str_mv | AT noriononomura finalanalysisofpostmarketingsurveillanceforavelumabaxitinibinpatientswithrenalcellcarcinomainjapan AT taitoito finalanalysisofpostmarketingsurveillanceforavelumabaxitinibinpatientswithrenalcellcarcinomainjapan AT masashisato finalanalysisofpostmarketingsurveillanceforavelumabaxitinibinpatientswithrenalcellcarcinomainjapan AT makikomorita finalanalysisofpostmarketingsurveillanceforavelumabaxitinibinpatientswithrenalcellcarcinomainjapan AT mieogi finalanalysisofpostmarketingsurveillanceforavelumabaxitinibinpatientswithrenalcellcarcinomainjapan AT masahirokajita finalanalysisofpostmarketingsurveillanceforavelumabaxitinibinpatientswithrenalcellcarcinomainjapan AT mototsuguoya finalanalysisofpostmarketingsurveillanceforavelumabaxitinibinpatientswithrenalcellcarcinomainjapan |